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Abstract 
 
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the 
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we 
sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor 
microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We 
demonstrate that the PARP inhibitor olaparib induces CD8+ T cell infiltration and activation 
in vivo, and that CD8+ T cell depletion severely compromises anti-tumor efficacy. Olaparib-
induced T cell recruitment is mediated through activation of the cGAS/STING pathway in 
tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-
deficient compared to HR-proficient TNBC cells and in vivo models. CRISPR-knockout of 
STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish 
olaparib-induced T cell infiltration in vivo. These findings elucidate an additional mechanism 
of action of PARP inhibitors and provide rationale for combining PARP inhibition with 
immunotherapies for the treatment of TNBC. 
 
Significance 
 
This work demonstrates cross-talk between PARP inhibition and the tumor 
microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that 
governs CD8+ T cell recruitment and anti-tumor efficacy. The data provide novel insight into 
the mechanism of action PARP inhibitors in BRCA-associated breast cancer. 
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Introduction 
Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease 
that constitutes 10-20% of breast cancer cases and is associated with poor overall survival 
and a high probability of distant recurrence and death (1,2). Conventional chemotherapy 
has been the standard-of-care, but initial remissions are often short, and advanced disease 
remains incurable (2). 
 
A subset of TNBCs are BRCA-associated and are deficient in homologous recombination 
(HR) repair (2). HR deficiency and inhibition of poly(ADP-ribose) polymerase (PARP) have 
been shown to produce synthetic lethality by a variety of mechanisms related to catalytic 
inhibition of the PARP enzyme and trapping of PARP-DNA complexes (3). Consequently, 
among BRCA-associated breast cancers, agents such as olaparib and talazoparib have 
improved the rates of response and progression-free survival compared to standard 
chemotherapy (4,5). Despite this promising therapeutic efficacy, treatment with PARP 
inhibitors have been complicated by both de novo and acquired resistance, which has led 
to the development of combinations with several HR-disrupting strategies in order to 
sensitize or re-sensitize cancer cells (3). 
 
There has also been substantial interest in the combination of PARP inhibition with immune 
checkpoint blockade, with combinatorial clinical trials ongoing in breast and other cancer 
types (6). Reports on the interaction of PARP inhibition with the immune microenvironment 
have shown variable results in preclinical breast cancer models.  In the syngeneic model 
EMT6, PARP inhibition was shown to decrease T cell infiltration and increase PD-L1 
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expression via GSK3β inactivation, contributing to immunosuppression that was reversed 
by addition of an anti-PD-L1 antibody.  Consequently, the combination of PARP inhibitor 
therapy with anti-PD-L1 blockade led to tumor growth inhibition (7).  In contrast, in a BRCA1-
deficient TNBC humanized mouse xenograft model PARP inhibition was associated with an 
increased T cell infiltrate and activated interferon signaling (8).   Of note, long-term PARP 
inhibition in cell line and tumor xenograft models has not been associated with an increase 
in mutational load, suggesting alternative mechanisms for immuno-modulatory effects (9).  
To this end, in DNA damage response-deficient TNBC cells, endogenous S-phase damage 
was shown to activate the cyclic GMP-AMP synthase (cGAS)/Stimulator of interferon genes 
(STING) pathway of cytosolic DNA sensing, leading to proinflammatory cytokine production 
(10).  
 
We hypothesized that PARP inhibition might activate STING-dependent signaling in BRCA-
associated TNBC, leading to an anti-tumor immune response. Here, we show that treatment 
with the PARP inhibitor olaparib results in the recruitment of CD8+ T cells in a BRCA1- and 
TP53-deficient genetically-engineered mouse model (GEMM) of TNBC, and that CD8+ T cell 
depletion diminishes the anti-tumor efficacy. Olaparib-induced pro-inflammatory cytokine 
production and subsequent T cell infiltration is dependent on cGAS/STING pathway 
activation exclusively in tumor cells and is more prominent in HR-deficient compared to HR-
proficient TNBC cells and in vivo models. Our findings uncover a novel mechanism of action 
of PARP inhibitors and provide additional mechanistic rationale for combining PARP 
inhibition with immunotherapies for the treatment of BRCA-associated TNBC. 
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Results 
Efficacy of PARP inhibition depends on recruitment of CD8+ T cells 
We evaluated the efficacy of olaparib in tumors derived from the K14-Cre-Brca1f/f;Tp53f/f 
immunocompetent GEMM of TNBC, where spontaneous mammary carcinomas develop 
after approximately 7 months (11). Individual tumors from this model were transplanted to 
immunocompetent FVB/129P2 syngeneic mice or to severe combined immunodeficient 
(SCID) mice and were treated with vehicle or olaparib. In immunocompetent mice, olaparib-
treated tumors rapidly regressed, and in some mice completely cleared. Although 
resistance to olaparib, evidenced by tumor progression, developed between 100-300 days 
(Supplementary Fig. S1A), olaparib promoted long-term survival, that was increased 16-
fold compared to vehicle (Fig. 1A). Notably, the median survival of olaparib-treated SCID 
mice was significantly lower (103 days) than the median survival of similarly treated 
immunocompetent mice (241 days) (Fig. 1A), suggesting that an intact immune system is 
required for an optimal response.  To confirm the requirement of an immune response for 
the anti-tumor efficacy of olaparib, we treated immunocompetent mice with olaparib in the 
presence of an anti-CD8 antibody. CD8+ T cell depletion, as verified by flow-cytometric 
analysis (Supplementary Fig. S1B), markedly accelerated tumor growth (Supplementary 
Fig. S1A) and significantly reduced the median survival of olaparib-treated mice from 241 
to 139 days (Fig. 1A). These findings corroborate that CD8+ T cells contribute to the 
therapeutic efficacy of PARP inhibition. 
 
We next sought to define the effects of olaparib on the immune microenvironment of TNBC.  
Immunohistochemical (IHC) analysis of tumors from immunocompetent mice showed that 
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olaparib significantly increases CD3+ cells and CD8+ T cells as early as 3 days after 
treatment (Supplementary Fig. S1C), as well as at 5 (Fig. 1B and C) and 10 days 
(Supplementary Fig. S1C). Importantly, CD8+ T cell recruitment was accompanied by an 
increase in granzyme B-positive CD8+ cells (Fig. 1B and C), indicative of cytolytic function. 
Flow cytometric analysis of immune cell subsets (see Supplementary Fig. S2 for gating 
strategy) in tumors treated with olaparib for 5 days showed that PARP inhibition significantly 
increases total hematopoietic cell and T cell counts, as measured by CD45 and CD3 
staining, respectively (Fig. 1D). Consistent with our IHC analysis, the proportion of CD8+ T 
cells among CD45+ and total live events, as well as granzyme B expression, were 
significantly increased in response to olaparib (Fig. 1D). While olaparib also increased CD4+ 
T cells, the proportion of T regulatory FoxP3+CD4+ T cells (Tregs) was not significantly 
affected (Supplementary Fig. S1D), implying that olaparib might be increasing CD4+ T-helper 
cells, which could further contribute to an effective immune response. T cell recruitment and 
activation in response to olaparib was reproduced in 2 additional independent experiments 
(Supplementary Fig. S1E). Olaparib not only augmented granzyme B expression in CD8+ 
T cells but also in natural killer (NK) cells (Supplementary Fig. S1E), suggesting activation 
of both innate and adaptive immune responses. In addition, as the proportion of tumor cells 
(EpCAM+) decreased in response to PARP inhibition, the microenvironment became 
populated with T cells (CD3+) and myeloid cells (CD11b+CD11c+) (Fig. 1E and 
Supplementary Fig. S1D). These results demonstrate that PARP inhibition can activate a 
productive anti-tumor immune response in BRCA-deficient breast tumors and that 
recruitment of cytotoxic CD8+ T cells is required for maximal therapeutic response.  
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To assess whether T cell infiltration in response to PARP inhibition also occurs in BRCA-
proficient TNBC we established tumors using the KB1P-G3 cell line, derived from our 
GEMM, and a BRCA-reconstituted isogenic cell line (12,13) (Fig. 1F). Treatment with 
olaparib caused accumulation of significantly higher CD3+, CD8+ and granzyme B-positive 
CD8+ T cell proportions in BRCA-deficient KB1P-G3 compared to KB1P-G3+BRCA1 tumors 
(Fig. 1G). Therefore, PARP inhibition potently induces cytotoxic T cell recruitment and 
activation in BRCA-deficient but not BRCA-proficient TNBC models.  
 
Olaparib activates the STING pathway in the K14-Cre-Brca1f/fTp53f/f TNBC GEMM 
The cGAS/STING pathway, triggered by cytosolic DNA, has been established as a critical 
activator of anti-tumor immune responses (14).  To determine whether olaparib-induced 
cytotoxic T cell recruitment is mediated through cGAS/STING signaling, we examined 
STING pathway activation in the KB1P-G3-/+BRCA1 isogenic paired cell lines. We 
assessed the presence of cytosolic DNA and observed that the DNA sensor cGAS, which 
displayed both nuclear and cytoplasmic localization, was found associated with cytoplasmic 
micronuclei (Fig. 2A), previously shown to precede cGAS/STING activation (15). Treatment 
with olaparib significantly increased formation of cGAS-bound micronuclei in KB1P-G3 but 
not KB1P-G3+BRCA1 cells (Fig. 2A). Next, we assessed the activation of the STING 
pathway effector TANK-binding kinase 1 (TBK1) by analysis of its activating Ser172 
phosphorylation (16) and found that olaparib induced TBK1 phosphorylation in KB1P-G3 
but not KB1P-G3+BRCA1 cells (Fig. 2B). We also measured expression of IFN regulatory 
factor 3 (IRF3), activated downstream of TBK1 by phosphorylation on Ser396 (17). pIRF3 
fluorescence intensity was significantly higher in BRCA1-deficient compared to proficient 
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KB1P-G3 cells treated with olaparib (Fig. 2C). We then asked whether TBK1/IRF3 activation 
correlates with DNA damage accumulation. Formation of g-H2AX foci, indicative of DNA 
strand breaks, was induced in both olaparib-treated KB1P-G3 and KB1P-G3+BRCA1 cells 
(Fig. 2C). However, compared to KB1P-G3+BRCA1, KB1P-G3 cells displayed significantly 
more  g-H2AX foci (Fig. 2C). To assess whether olaparib-induced cGAS/STING activation 
results in proinflammatory cytokine production, we measured expression of IFNβ, known to 
be primarily induced by STING-dependent signaling (14,18). Olaparib significantly 
upregulated the mRNA levels of IFNβ in KB1P-G3 but not KB1P-G3+BRCA1 cells (Fig. 2D). 
We also examined the expression of the proinflammatory chemokines CCL5 and CXCL10 
that have been associated with STING/TBK1/IRF3-dependent signaling and T cell 
infiltration in TNBC (10,19–21). Similar to IFNβ, the mRNA levels of CCL5 and CXCL10 
were significantly higher in olaparib-treated KB1P-G3 cells compared to their BRCA1-
reconstituted pair (Fig. 2D).  
 
We further assessed STING/TBK1/IRF3 pathway activation in K14 cells, another cell line 
derived from the BRCA1-deficient GEMM (22). We observed a 1500-fold increase in cGAS-
synthesized cGAMP levels following olaparib treatment of K14 cells (Supplementary Fig. 
S3A). Flow-cytometric analysis of phospho-TBK1Ser172, phospho-IRF3Ser396 and g-H2AX 
(phospho-H2AXSer139) expression in olaparib-treated K14 cells demonstrated a dose-
dependent significant increase, comparable to that of the STING agonist DMXAA 
(Supplementary Fig. S3B) (gating strategy shown in Supplementary Fig. S3C). Increased 
phosphorylation of IRF3 and H2AX in response to olaparib was confirmed by 
immunofluorescence microscopy analysis (Supplementary Fig. S3D). Similar to KB1P-G3 
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cells, olaparib significantly upregulated the mRNA levels of IFNβ, CCL5 and CXCL10 
(Supplementary Fig. S3E). Taken together, the data in the KB1P-G3-/+BRCA1 and K14 cells 
indicate that PARP inhibition potently activates the cGAS/STING pathway in BRCA1-
deficient but not BRCA1-profcient murine tumor cells, leading to type I IFN and 
proinflammatory chemokine production, known to recruit CD8+ T cells (20,21,23). 
 
Since the cGAS/STING pathway has previously been shown to be activated in DCs (14), 
we assessed whether olaparib activates the pathway in both tumor and DCs in vivo by 
flow-cytometric analysis of harvested tumors treated with vehicle or olaparib (gating 
strategy shown in Supplementary Fig. S4A and B). PARP inhibition significantly increased 
the proportion of EpCAM+pIRF3+ cells out of total live events and produced a trend toward 
increased EpCAM+pTBK1+ cells, demonstrating activation of STING/TBK1/IRF3 signaling 
in tumor cells in vivo (Fig. 3A). In addition, olaparib significantly increased the proportion of 
CD11c+CD11b- DCs expressing pTBK1 and pIRF3 (Fig. 3B). pTBK1 and pIRF3 levels were 
also significantly upregulated in DCs expressing major histocompatibility complex (MHC) 
class II, indicative of DC maturation and antigen presentation ability (Fig. 3B). The total 
proportion of mature DCs also increased significantly in response to olaparib (Fig. 3B). 
Consistent with STING/TBK1/IRF3 pathway activation, mRNA expression analysis of these 
tumors showed that olaparib increases IFNβ and CCL5 expression (Fig. 3C). Assessment 
of TBK1/IRF3 signaling in the KB1P-G3-/+BRCA1 isogenic tumor model revealed 
significantly higher proportions of EpCAM+pTBK1+ and EpCAM+pIRF3+ tumor cells in 
olaparib-treated KB1P-G3 tumors compared to KB1P-G3+BRCA1 (Fig. 3D), consistent with 
our in vitro observations.  
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To determine whether the observed activation of TBK1/IRF3 signaling in DCs results from 
a direct effect by PARP inhibitors, we differentiated dendritic cells from bone marrow and 
cultured them in the presence of olaparib. While the STING agonist DMXAA potently 
induced TBK1 phosphorylation in DCs resulting in their activation (CD40+) and maturation 
(MHCII+), olaparib did not affect the expression of these markers (Supplementary Fig. S5A 
and B). These findings suggest that PARP inhibition potently activates the cGAS/STING 
pathway in BRCA1-deficient but not proficient tumor cells in vivo, resulting in subsequent 
activation of TBK1/IRF3 signaling in DCs that stimulates antigen presentation and 
consequently CD8+ T cell infiltration and activation. 
 
Olaparib activates the STING pathway more potently in HR-deficient human TNBC 
cells compared to HR-proficient cells 
We next assessed the ability of olaparib to activate the cGAS/STING pathway in human 
TNBC cells. We utilized the BRCA1-deficient MDA-MB-436 cells and its isogenic BRCA1-
reconstituted pair (Supplementary Fig. S6A and B), as well as MDA-MB-436 cells with 
acquired olaparib resistance, generated after prolonged PARP inhibitor exposure (24) 
(Supplementary Fig. S6B). The mechanism of resistance was shown to be associated with 
TP53BP1 mutation, facilitating BRCA1-independent end resection, as well as HSP90-
mediated stabilization of the mutant form of BRCA1 capable of interacting with PALB2-
BRCA2, facilitating RAD51 loading and subsequently HR repair (24). Olaparib significantly 
increased the number of cGAS-bound micronunclei in MDA-MB-436 control cells, but not 
in BRCA1-reconstituted or PARP inhibitor-resistant cells (Fig. 4A). Consistent with cGAS 
activation, cGAMP synthesis was significantly induced in olaparib-treated MDA-MB-436 
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control cells but not BRCA1-reconstituted or PARP inhibitor-resistant cells (Fig. 4B). Flow 
cytometric analysis showed that TBK1 phosphorylation in response to olaparib is impaired 
in PARP inhibitor-resistant and BRCA1-repleted MDA-MB-436 cells, as compared to 
parental and control cells (Fig. 4C). The same results were obtained when pTBK1 
expression was measured by immunoblotting (Fig. 4D). To confirm these findings, we 
treated a panel of human TNBC cell lines with olaparib according to their 7-day IC50 values 
(Supplementary Fig. S6B) and assessed pTBK1 expression. In line with our previous 
observations, olaparib potently induced TBK1 phosphorylation in the HR-deficient MDA-
MB-436 cells but not in the BRCA1 wild type (wt) HR-proficient MDA-MB-231 cells (Fig. 
4E). Less robust TBK1 phosphorylation occurred following olaparib treatment in BRCA1-
mutant HCC1937 cells, which have previously been shown to retain functional HR 
proficiency (25) (Fig. 4E). The same pattern of pTBK1 activation was observed when these 
3 cell lines were treated with the same doses of olaparib (Supplementary Fig. S6C). Of 
note, STING protein levels did not correlate with pTBK1 activation in these cells 
(Supplementary Fig. S6C). In fact, STING was overexpressed in PARP inhibitor-resistant 
MDA-MB-436 cells, suggesting that the inability of PARP inhibition to activate TBK1/IRF3 
signaling is not a result of reduced STING expression (Supplementary Fig. S6D).  
 
Similar to pTBK1, olaparib significantly increased the proportion of pIRF3-positive MDA-
MB-436 parental and control cells, but not of BRCA1-reconstituted or PARP inhibitor-
resistant cells (Fig. 4F). Cisplatin, used as a positive control, induced pIRF3 to the same 
extent as olaparib (Fig. 4F). Additionally, pIRF3 fluorescence intensity as measured by 
immunofluorescence microscopy was significantly reduced in the presence of BRCA 
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expression following treatment with olaparib (Supplementary Fig. S6E). TBK1/IRF3 
activation correlated with the induction of DNA damage as measured by flow cytometry (Fig. 
4G) and immunofluorescence microscopy (Supplementary Fig. S6E). In agreement with 
these observations, olaparib significantly stimulated IFNβ production in MDA-MB-436 
control, but not BRCA1-reconstituted or PARP inhibitor-resistant cells (Fig. 4H). While IFNβ 
expression was exclusively induced in the HR-deficient parental MDA-MB- 436 cells, there 
was a trend toward increased CCL5 and CXCL10 production in the BRCA1-reconstituted 
HR-proficient cells (Fig. 4H), suggesting that these chemokines are possibly induced by a 
STING-independent mechanism. IRF3 activation and proinflammatory cytokine production 
in response to olaparib was also evident in HCC1937 cells (Supplementary Fig. S6F).  
 
Moreover, we confirmed that cGAS/STING pathway activation is not specific to olaparib and 
that the PARP inhibitors veliparib and talazoparib also induce cGAMP synthesis, TBK1 
phosphorylation and proinflammatory cytokine production more potently in BRCA-deficient 
compared to proficient cells (Supplementary Fig. S7A-D). In summary, these data suggest 
that PARP inhibitors activate the STING/TBK1/IRF3 pathway and subsequent type I IFN 
production more potently in HR-deficient compared to HR-proficient human TNBC cells, 
and this correlates with induction of DNA damage more than STING protein expression. 
 
STING activation in tumor cells is required for olaparib-induced T cell recruitment  
In order to assess the requirement of STING pathway activation in tumor cells for the 
production of proinflammatory cytokines in response to PARP inhibition, we used 
CRISPR/Cas9-mediated knockout (KO) of STING in the K14 cell line derived from the 
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BRCA GEMM. CRISPR-mediated KO of STING (STING KO), confirmed by immunoblot 
analysis (Fig. 5A), did not affect the efficacy of olaparib in vitro (Supplementary Fig. S7E). 
However, olaparib-induced TBK1 phosphorylation was completely abolished in STING-
depleted cells compared to the CRISPR/Cas9 control cells (Fig. 5A). The same result was 
obtained in response to veliparib and talazoparib (Fig. 5A) (IC50 values are shown in 
Supplementary Fig. S7E). Consequently, IFNβ, CCL5 and CXCL10 production in response 
to olaparib, veliparib and talazoparib (Fig. 5B) was blocked in cells lacking STING, indicating 
that PARP inhibitor-induced proinflammatory cytokine production is mediated through the 
STING/TBK1/IRF3 pathway. Of note, total STING protein levels were decreased in 
response to PARP inhibition, likely due to a negative feedback loop leading to STING 
degradation, as previously reported (26–28). 
 
STING repletion in the KO cells (KO+STING) rescued olaparib-induced TBK1 
phosphorylation as compared to STING KO cells with empty vector (KO+EV) (Fig. 5C). 
pTBK1 induction in olaparib-treated STING-repleted cells resembled pTBK1 levels in 
DMXAA-treated control cells (Fig. 5C). Reconstitution of STING expression in the KO cells 
also rescued type I IFN and proinflammatory chemokine production (Fig. 5D). To determine 
whether the DNA sensor cGAS is necessary for PARP inhibitor-induced TBK1/IRF3 
signaling, we depleted cGAS from K14 cells. As seen with STING depletion, cGAS KO 
completely impaired olaparib- and veliparib-induced TBK1 activation (Fig. 5E) and increase 
in expression of proinflammatory cytokines (Fig. 5F), confirming that the cGAS/STING 
pathway is required for PARP inhibitor-induced proinflammatory signaling.  
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To assess the requirement of STING pathway activation for PARP inhibitor-induced CD8+ T 
cell recruitment in vivo, we generated tumors from CRISPR/Cas9 control and STING KO 
cells in syngeneic mice. The tumors maintained depleted levels of STING (Fig. 6A). We 
next performed flow cytometric analysis of harvested control and STING KO tumors treated 
with vehicle or olaparib for 5 days (gating strategies same as in Supplementary Fig. S2 and 
S4). Consistent with our previous results, olaparib significantly increased the proportion of 
infiltrating T cells in the CRISPR/Cas9 control tumors with increased CD8+ T cells and 
granzyme B production (Fig. 6B). In contrast, olaparib-induced CD8+ T cell recruitment and 
granzyme B expression was abolished in the STING KO tumors (Fig. 6B). Importantly, 
olaparib-induced IRF3 activation in both tumor and dendritic cells was also impaired when 
STING was depleted, supporting the notion of cancer cell-mediated DC activation (Fig. 6C).  
 
To directly examine the requirement of STING in the anti-tumor efficacy of olaparib we 
treated CRSIPR/Cas9 control and STING-depleted tumors with olaparib and measured 
tumor volume. We observed that the growth of STING KO tumors was delayed compared 
to control tumors, implying that STING pathway activation might have a pro-tumorigenic 
role as some studies have suggested (29). Nonetheless, tumor burden in response to 
olaparib was significantly reduced in mice bearing control tumors, but not STING-depleted 
tumors, suggesting that STING depletion impairs the efficacy of PARP inhibition (Fig. 6D). 
These findings demonstrate that tumor cell activation of the STING/TBK1/IRF3 pathway 
and subsequent production of type I IFNs in response to PARP inhibition is necessary for 
recruitment and activation of cytotoxic CD8+ T cells and consequent anti-tumor efficacy. 
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Discussion 
In this work, we provide evidence that PARP inhibition triggers an anti-tumor immune 
response in a BRCA1- and TP53-deficient model of TNBC through activation of the 
cGAS/STING pathway of cytosolic DNA sensing, and that the anti-tumor efficacy of PARP 
inhibitors is critically dependent on the recruitment of granzyme B-positive CD8+ T cells. We 
demonstrate that the STING/TBK1/IRF3 pathway is activated in vivo in BRCA1-deficient 
but not proficient tumor cells with subsequent paracrine activation in DCs, and that depletion 
of STING exclusively in tumor cells is sufficient to abolish PARP inhibitor-induced cytotoxic 
CD8+ T cell infiltration and anti-tumor efficacy.  
 
Despite a substantial increase in total CD4+ T cells, we did not observe a significant change 
in the numbers of immunosuppressive CD4+FoxP3+ Tregs in response to olaparib in our 
model.  In other model systems, the PARP inhibitor talazoparib has been associated with 
an increase in Tregs (30). Further studies will be required to determine the precise effects 
of PARP inhibition on CD4+ T cell subsets and the role of CD4+ T cell infiltration in the anti-
tumor efficacy of PARP inhibitors. 
 
In contrast to our findings, it has recently been reported that olaparib decreases cytotoxic 
CD8+ T cell fractions, as measured by Cytometry by Time of Flight (CyTOF), in the EMT6 
model of TNBC, and that addition of an anti-PD-L1 antibody restores CD8+ T cell numbers 
(7). The failure of olaparib to recruit T cells in this model might account for the limited anti-
tumor efficacy that was observed and is likely to be attributed to the BRCA proficiency of 
this model, where STING pathway induction is substantially less robust than in a BRCA-
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deficient background. The more pronounced STING pathway activation in BRCA1-deficient 
tumors may explain the naturally higher lymphocyte infiltration of this subset when 
compared to other types of breast cancer (10). 
 
While the predominant cell type that produces type I IFNs in the tumor microenvironment 
are DCs, other cell types, including tumor cells themselves, are emerging as type I IFN 
producers (14). It has previously been demonstrated that DNA damage response-deficient 
breast tumor cells that display endogenous S-phase specific DNA damage activate the 
STING/TBK1/IF3 pathway, resulting in proinflammatory cytokine production and T cell 
recruitment (10). These findings are consistent with our observations that PARP inhibitor-
induced DNA damage, which occurs primarily in S phase, correlates with activation of the 
cGAS/STING pathway and that this response is more pronounced in HR-deficient 
compared to HR-proficient TNBC models. This translates to more robust T cell recruitment 
and activation in vivo. While PARP inhibition activates the STING pathway in both tumor 
and DCs in vivo, we did not find that olaparib directly induces TBK1/IRF3 signaling in bone 
marrow-isolated DCs ex vivo.  These results are indicative of tumor cell-mediated paracrine 
activation of the TBK1/IRF3 pathway in DCs that stimulates antigen presentation and are 
consistent with recent findings in BRCA-deficient ovarian cancer syngeneic and GEMM 
models (31). Consequently, we find that STING-mediated signaling exclusively within tumor 
cells is necessary and sufficient for cytotoxic CD8+ T cell infiltration of olaparib-treated 
tumors and therapeutic efficacy. 
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Beyond TNBC, the effects of PARP inhibition on the immune microenvironment and 
cGAS/STING pathway activation have been shown to extend to other tumor types as well.   
For example, in the BRCA-deficient ovarian cancer model BR5, talazoparib and veliparib 
have resulted in increased or unchanged CD8+ T cell infiltration, respectively (6, 7), with 
synergistic immune-mediated tumor clearance afforded by the addition of CTLA-4 blockade 
(10). The survival benefit produced by the CTLA-4 combination was T cell-mediated and 
dependent on increases in IFN-g production (10).  Additionally, in the BRCA-proficient ID8 
ovarian cancer model, PARP inhibition was shown to activate TBK1/IRF3 pro-inflammatory 
signaling with subsequent CD8+ T cell recruitment. PARP inhibitor efficacy was very 
modest, although these effects were associated with synergism of PARP inhibition with 
immune checkpoint blockade (32).  In contrast, while potent STING pathway activation in 
response to olaparib was observed in dendritic cells derived from ID8/BRCA1-null tumors 
and from a Tp53–/–,BRCA1–/–,Myc overexpressing ovarian GEMM, leading to T cell 
recruitment, these events did not occur in BRCA-proficient models (31). Taken together, 
these reports raise the question of the dependence on BRCA deficiency of PARP inhibitor-
mediated immune effects specifically in ovarian cancer.  In fact, in the clinical study of 
combined niraparib and pembrolizumab, responses occurred in ovarian cancer patients 
harboring BRCA wild-type tumors (33). In the breast cancer models examined here, STING 
pathway activation and immune responses were clearly more pronounced in the BRCA-
deficient setting. Notably, the majority of TNBC clinical responses to 
niraparib/pembrolizumab occurred among patients harboring BRCA mutations (6). 
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In the ovarian models, the efficacy of olaparib alone or in combination with immune 
checkpoint blockade was compromised in STING –/– mice, attributable to a loss of pathway 
activation in DCs (31,32).  Our results highlight the importance of intratumoral STING in the 
anti-tumor effects of olaparib, which stimulates pathway activation in host dendritic cells in 
a paracrine manner.   
 
Previously, PARP inhibition was shown to be a potential strategy for ERCC1-deficient non-
small cell lung cancer (NSCLC) (34).  Consistent with the role of the immune system in anti-
tumor activity, PARP inhibition has also been shown to activate a STING-mediated IFN 
response in ERCC1-deficient NSCLC cells (35).  In small cell lung cancer (SCLC) models, 
olaparib also activates the STING/TBK1/IRF3 pathway.  Although olaparib monotherapy did 
not lead to T cell recruitment or anti-tumor efficacy in vivo, these effects were reversed by 
the addition of PD-L1 blockade, and the efficacy of combined olaparib and immune 
checkpoint blockade was abolished by STING or cGAS knockdown in tumor cells (36).  
These results further support the importance of intratumoral STING for the activity of PARP 
inhibitor-based treatment. Similar findings were observed with the CHK1 inhibitor 
prexasertib in SCLC models (36), suggesting that STING pathway activation may be a 
common mechanism among DNA damage repair inhibitors.  
 
In summary, we have identified CD8+ T cell recruitment via cancer cell STING pathway 
activation as a critical determinant of the therapeutic efficacy of PARP inhibition in TNBC. 
These findings suggest that PARP inhibitors can enhance the anti-tumor immune response 
of TNBCs, which has been associated with improved prognosis (37–39). Importantly, these 
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results provide a further mechanistic rationale for combining PARP inhibition with 
immunotherapy. In a BRCA-deficient background, PARP inhibitor-mediated DNA damage 
may leverage the STING pathway to convert immunologically cold into hot tumors and 
sensitize to immune checkpoint blockade (30,40). In contrast, in BRCA-proficient tumors, 
where PARP inhibitor-induced DNA damage and STING-dependent type I IFN responses 
are limited, a direct STING agonist (41) may be the preferred combinatorial partner with 
immune checkpoint blockade. 
 
Methods 
 
Cell culture. Human cell lines were purchased from American Type Culture Collection 
(ATCC) between 2015 and 2017, maintained in the recommended medium and passaged 
up to 15 times. MDA-MB-436 cells with reconstituted BRCA1 expression and with acquired 
PARP inhibitor resistance have been previously described (24, 42). The K14 cell line was 
generated by removing breast tumors from K14-Cre Brca1f/fTrp53f/f females, seeding single-
cell suspensions in DMEM (Corning) supplemented with 10% FBS and passaging until 
phenotypical and growth rate stability were achieved (22). The murine isogenic cell line pair 
KB1P-G3-/+BRCA1 was generated and maintained as previously described (12,13). All cell 
lines were routinely tested for the presence of mycoplasma using the MycoAlert 
Mycoplasma Detection Kit (Lonza). For flow cytometry (FC) trypsinized cells were incubated 
in Zombie Aqua Fixable Viability dye (Biolegend) and processed according to the antibody 
(Supplementary Table S1) manufacturer’s protocol ID 407 and 404, for phospho-TBK1 and 
phospho-IRF3 analysis, respectively.  
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Viability assays. Cell viability was assessed by CellTiter-Glo (Promega) according to 
manufacturer’s guidelines. Viability was normalized to DMSO control and expressed as 
percentage. Survival curves were generated and IC50 values were derived using non-linear 
regression with the equation “[Inhibitor] vs. normalized response - Variable slope” 
(GraphPad Prism v7). 
 
Compounds. Olaparib (AZD-2281; Selleckchem) and talazoparib (BMN673; Selleckchem) 
were reconstituted in DMSO (100mM and 50mM, respectively). Veliparib (ABT-888; 10mM) 
and cisplatin (1mg/ml) were from Selleckchem and Fresenius Kabi, respectively. DMXAA 
(S1537; Selleckchem) was reconstituted in DMSO (50mM). 
 
In vivo studies. All animal experiments were conducted in accordance with Institutional 
Animal Care and Use Committee-approved protocols at Beth Israel Deaconess Medical 
Center and Dana-Farber Cancer Institute. Pieces from breast tumors generated in K14-Cre 
Brca1f/fTrp53f/f female mice were transplanted into the mammary pad of FVB/129P2 or 
SCID/BEIGE (CB17.Cg-PrkdcscidLystbg-J/Crl; Charles River) recipient females. FVB/129P2 
recipients were generated by breeding FVB females (Jackson Laboratories) and 129P2 
males (Envigo) and using the first-generation litters for experimentation. For KB1P-G3-
/+BRCA1 tumor generation 5 million cells mixed with Matrigel (Corning) were injected in the 
mammary fat pad of FVB/129P2 female mice. When tumors reached 15mm, mice were 
sacrificed, tumors were harvested and transplanted into recipient FVB/129P2 females. For 
efficacy studies treatments were started once the tumors reached 7mm in diameter and 
continued until tumors reached 20mm or 1000mm3 in volume, at which point mice were 
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euthanized. For flow cytometry studies mice bearing tumors of 150-300mm3 in volume were 
randomized in treatment groups, so that the average tumor volume in each group was the 
same. DMSO-reconstituted olaparib was diluted in PBS (Corning) immediately before 
intraperitoneal injection and administered at 50mg/kg daily. Anti-CD8 and IgG2b isotype 
control antibodies (BioXCell; #BE0117 and BE0090) were dissolved in PBS (Corning) and 
administered intraperitoneally at 0.2mg/dose twice per week. Tumors were measured every 
3-4 days using electronic calipers and tumor volumes calculated by using the ellipsoid 
formula for volume (L*W*W*pi/6). 
 
Immunohistochemistry. IHC was performed on the Leica Bond automated staining 
platform. The CD3 antibody (Cell Signaling Technologies (CST), #99940 clone D4V8L) and 
CD8 antibody (CST, #98941 clone D4W2Z) were run at 1:150 and 1:400 dilutions, 
respectively, using the Leica Biosystems Refine Detection Kit with EDTA antigen retrieval. 
The granzyme B antibody (R&D #AF1865 polyclonal) was run at 1:100 dilution using the 
Leica Biosystems Refine Detection Kit with citrate antigen retrieval. Appropriate control 
samples were stained using the respective optimized staining protocols and slides were 
scanned into the Aperio image analysis platform. Parameters for image analysis macros 
were developed on the control samples by adapting the membrane v9 or cytoplasmic v2 
algorithms as appropriate and used to analyze the CD3, CD8 or granzyme B stains, 
respectively. IHC analysis of CD8+ cells in Supplementary Fig. 1C was performed by 
manual counting of CD8+ and total cells in 10 fields/tumor. Images (20x magnification) were 
acquired using Zeiss Axioimager M1 microscope with Plan-Apochromat 20x/0.8 air.  
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Tumor digestion and FC. Mice were sacrificed at the indicated times and cardiac perfusion 
was performed. Tumors were extracted, finely minced, blended with the gentleMACS 
Dissociator (Miltenyi Biotec) and digested with MACS Miltenyi Tumor Dissociation Kit 
(Miltenyi Biotec #130-096-730) according to manufacturer’s instructions. Dissociated tumor 
cells were washed with RPMI-1640 medium and lysed with RBC Lysis Solution (Qiagen). 
Cells were resuspended in FACS buffer; PBS (Life Technologies) containing 0.5% BSA and 
2mM EDTA (Sigma-Aldrich). Zombie Aqua Fixable Viability Kit was applied to cells in 
combination with anti-mouse CD16/CD32 Fcγ receptor II/III blocking antibody (Affymetrix 
#14-0161-85) for 20min at RT, prior to incubation with primary antibodies (Supplementary 
Table S1) for 1h at 4°C. Cells were fixed and permeabilized using the FoxP3/Transcription 
Factor Staining Buffer Set (Affymetrix #00-5523-00), according to the manufacturer’s 
guidelines, and incubated with antibodies for intracellular antigens overnight at 4°C. Next 
day cells were washed, resuspended in PBS and analyzed using a BD LSRFortessa flow 
cytometer. Compensation was performed manually on BD FACS Diva using single color 
and isotype controls, in line with our previous work (43). Signal threshold definition was 
defined using all-stain, unstained and isotype controls. Analysis was performed on FlowJo 
V10. In each experiment a T cell panel and a pTBK1-pIRF3 panel were setup; gating 
strategies for each panel are provided in figure S2 and S4, respectively.  
 
CRISPR/Cas9-mediated knockout, STING repletion and tumor generation. The gRNA 
sequences GTCCAAGTTCGTGCGAGGCTAGG or ATATTCTTGTAGCTCAATCC 
targeting murine STING or cGAS, respectively, were cloned into the lenti-CRISPR/Cas9v2 
vector (Addgene, #52961) according to the Zhang lab protocol (25). The scrambled gRNA 
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sequence CACCGCGTGATGGTCTCGATTGAGT was used as a negative control. Viral 
infection was performed as described by the RNAi consortium (TRC, Broad Institute) 
laboratory protocol “Lentivirus production of shRNA or ORF-pLX clones” and single clones 
were isolated following puromycin selection (2μg/ml; Sigma-Aldrich #P8833) for 3 weeks. 
For generation of STING-repleted cells, STING KO cells were transfected with pUNO1-
mSTINGwt-HA3x (InvivoGen) or pUNO1 empty vector (EV) using FuGENE 6 transfection 
reagent (Promega). Plasmid-incorporated cells were enriched by blasticidin selection (30 
μg/ml; Life Technologies #A1113903) for 3 weeks and polyclonal populations were used in 
experiments. Tumor generation was performed as stated above for the KB1P-G3 model.  
 
Immunofluorescence microscopy. Cells were seeded on chamber slides (Thermo 
Scientific™ Nunc™ Lab-Tek™) and treated as specified. For picogreen-cGAS staining cells 
were incubated with pico488 DNA quantification reagent (Lumiprobe Life Science Solutions; 
1:500) for 2h at 37°C. For all immunofluorescence staining cells were washed in PBS, fixed 
in 4% formaldehyde/PBS (10min, RT) and permeabilized in 0.25% Triton/PBS (20min, RT). 
Blocking was performed in 5% BSA/0.1% Triton/PBS (30min, RT), followed by incubation 
with primary antibodies (Supplementary Table S1) in blocking buffer (1h, 37°C). Cells were 
washed in PBS and incubated with secondary antibodies (Supplementary Table S1) in 
blocking buffer (1h, RT), followed by washing and mounting on coverslips using ProLong 
Gold antifade reagent with DAPI (#P36935, Life Technologies). Cells were imaged using 
Nikon widefield confocal microscope at the specified magnification and images were 
analyzed using ImageJ/Fiji software. For micronuclei and γH2A.X foci quantification at least 
50 and 150 nuclei were counted in 5-10 fields, respectively. For quantification of 
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fluorescence intensity, the area and integrated density of equally exposed images were 
measured. Background fluorescence was calculated by measuring the mean grey value 
from 3 different areas on the image containing no cells. The corrected integrated density 
was calculated by multiplying the area of the image by the background fluorescence and 
subtracting the product from the integrated density of the entire image. This was divided by 
the number of cells in the image to give the corrected integrated density per cell (44). 
 
cGAMP ELISA. cGAMP ELISA (Cayman chemical) was performed on cell lysates 
according to manufacturer’s instructions. Briefly, cells were lysed and protein concentration 
was determined by Bio-rad protein assay. Titration was performed to determine ideal 
concentration of protein, which was 25 μg for human and 50 μg for mouse lysates. Two 
technical replicates were used per biological replicate. 
 
Quantitative PCR. RNA was isolated using the PureLinkTM RNA kit (Invitrogen) and 
reversed transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems), according to the manufacturer’s guidelines. qPCR was performed using 
Power SYBR Green PCR MasterMix (Applied Biosystems) in a QuantStudio 3 Real-Time 
PCR System (Applied Biosystems). Primer sequences (5’-3’): human IFNβ forward 
AACTTGCTTGGATTCCTACAAAG and reverse TATTCAAGCCTCCCATTCAATTG, 
mouse IFNβ forward CCAGCTCCAAGAAAGGACGA and reverse 
CGCCCTGTAGGTGAGGTTGAT, human CCL5 forward TGCCCACATCAAGGAGTATTT 
and reverse CTTTCGGGTGACAAAGACG, mouse CCL5  forward 
GCTCCAATCTTGCAGTCGTG and reverse GCTCCAATCTTGCAGTCGTG, human 
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CXCL10 forward GGCCATCAAGAATTTACTGAAAGCA and reverse 
TCTGTGTGGTCCATCCTTGGAA, mouse CXCL10 forward 
CCAAGTGCTGCCGTCATTTT and reverse CTCAACACGTGGGCAGGATA, human 
GAPDH forward GAGTCAACGGATTTGGTCGT and reverse 
TTGATTTTGGAGGGATCTCG, mouse GAPDH forward ACCACAGTCCATGCCATCAC 
TCCACCACCCTGTTGCTGTA and reverse.  
 
Bone marrow derived dendritic cells. Dendritic cells were derived from FVB/129P2 F1 
mice as follows: Using a 25G 5/8" needled syringe bone marrow was flushed out of femurs 
with HBSS (Gibco) into a 50ml conical tube. Flushed bone marrow was filtered through a 
70µM cell strainer (Fisherbrand) into another 50ml tube. Cells were spun down (5min, 
1500rpm, 4°C) and pellet was resuspended in ACK buffer (Gibco) to lyse red blood cells. 
Cells were washed and resuspended in growing media (RPMI/1% Penicillin-
Streptomycin/0.05 mM 2-Mercaptoethanol/10% heat inactivated FBS; all from Gibco) 
supplemented with 200 ng/ml flt3l (Peprotech) for 7 days.  At day 7 cells were collected, 
counted and seeded in the presence of DMSO, DMXAA (5 μg/ml) or olaparib (5 μM). After 
20h cells were collected, resuspended in FACS buffer and stained for flow cytometry as 
detailed above (“tumor digestion and FC” section). 
 
Immunoblotting. Cells were lysed in RIPA buffer (Boston Bioproducts) supplemented with 
protease and phosphatase inhibitors (Calbiochem), quantitated for protein using the BCA 
Protein Assay Kit (Pierce) and equal amounts of protein were resolved by SDS-PAGE. 
Membranes were blocked in 5% milk/TBS-T (Boston Bioproducts) and incubated with 
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antibodies (Supplementary Table S1). Immunodetection was performed using SuperSignal 
West Pico and Femto Chemiluminescent Substrate (ThermoFisher Scientific). Blot stripping 
was performed using Restore PLUS Western Blot Stripping Buffer (Life Technologies) 
according to manufacturer’s guidelines. Protein levels were quantified by densitometric 
analysis using ImageJ/Fiji. Phosphorylated protein levels were normalized to total 
proteinband then to loading control and expressed as fold-change versus control DMSO. 
Immunoblots shown are representative of 3 independent experiments.  
 
Statistical analysis. Statistical analyses were performed using GraphPad Prism v7 and 
v8. For comparison of two sets of measurements unpaired t-test was performed. Unpaired 
t test with Welch's correction was used when sample variances were not equal, as defined 
by the Brown-Forsythe test. For two sets of fold-change measurements one-sample t-test 
was used (measurements were compared to the value of 1). For comparison of three or 
more sets of unpaired measurements one-way ANOVA was performed with Tukey's post-
hoc test if all sets were analyzed, or Sidak’s post-hoc test if selected relevant pairs were 
analyzed (as recommended by GraphPad Prism). When the Brown-Forsythe test indicated 
that sample variances were not equal the Brown-Forsythe ANOVA test was performed with 
Games-Howell post-hoc test. When two variables were present two-way ANOVA with 
Tukey's post-hoc test was performed. For comparison of three or more sets of 
measurements that did not follow a normal distribution e.g. fold-change measurements, the 
Kruskal-Wallis test with Dunn's post-hoc test was performed. Normality was examined using 
the Kolmogorov-Smirnov test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Figure 1. Efficacy of PARP inhibition depends on recruitment of CD8+ T cells.  
(A) Tumor chunks from the BRCA GEMM were transplanted in syngeneic FVB/129P mice 
(8-10/group), which were treated with vehicle or olaparib along with an isotype (iso) 
control or an anti-CD8 antibody. Median survival is shown in brackets. Tumors were also 
transplanted in SCID mice (5-6/group) and treated with vehicle or olaparib. Statistical 
analysis was performed using the Log-rank (Mantel-Cox) test. (B-C) Vehicle (VEH) and 
olaparib (OLA)-treated tumors were harvested 5 days post-treatment, fixed and subjected 
to immunohistochemical analysis for CD3, CD8 and Granzyme B expression, which was 
quantified using algorithms. Error bars represent standard deviation (SD). Statistical 
analyses were performed using unpaired t-tests or unpaired t-tests with Welch’s 
correction if variances were significantly different. Representative images are shown at 
20X magnification. Scale Bar, 200 μm. (D-E) Tumors from vehicle or olaparib-treated 
mice (n=9) were harvested 5 days post-treatment and analyzed by flow cytometry. Scatter 
plots show significant increases in CD45+, CD3+, CD8+ and granzyme-B+ cells in olaparib-
treated animals. Pie charts show the proportions of different cell types (as % of total live 
events) in the tumor microenvironment. Error bars represent SD. Statistical analyses were 
performed using unpaired t-tests or unpaired t-tests with Welch’s correction. (F) 
Immunoblot shows BRCA1 expression in KB1P-G3 and KB1P-G3+BRCA1 cells. (G) 
KB1P-G3 and KB1P-G3+BRCA1 tumors from 5 vehicle or olaparib-treated mice were 
harvested 5 days post-treatment and analyzed by flow cytometry. Scatter plots show % 
CD3+, CD8+ and granzyme B+ cells. Error bars represent SD. Statistical analyses were 
performed using two-way ANOVA with Tukey's post-hoc test.  
 
Figure 2. Olaparib activates the cGAS/STING pathway in cells derived from the K14-
Cre-Brca1f/fTp53f/f GEMM. 
The murine isogenic cell line pair KB1P-G3-/+BRCA1 derived from the GEMM was 
treated with DMSO (0 μM Olaparib) or the indicated doses of olaparib. (A) At 72h post-
treatment cells were stained with picogreen, fixed and subjected to immunofluorescence 
staining for cGAS. Representative images of picogreen (green) and cGAS (red) stained 
micronuclei are shown (60x magnification). Scale bar, 8 μm. The number of cGAS-
colocalized micronuclei was quantified and expressed as % of total nuclei. Error bars 
represent standard error of the mean (SEM) of 2 independent experiments. Statistical 
analysis was performed using two-way ANOVA with Tukey's post-hoc test. (B) At 72h 
post-treatment cells were subjected to immunoblotting for phosphorylated (pTBK1Ser172) 
and total TBK1 expression with vinculin as a loading control. Markers indicate molecular 
weight (MW) (kDa). Numbers below the blots represent normalized pTBK1 protein levels 
quantified by densitometric analysis. (C) At 24h post-treatment cells were fixed and 
subjected to immunofluorescence staining for γ-H2AX (pH2AX Ser139) and pIRF3Ser396. 
Representative images of DAPI (blue), γ-H2AX (green) and pIRF3 (red) stained cells are 
shown (20x magnification); scale bar, 8 μm (left panel). The number of cells displaying 
>5 γH2AX foci was quantified, and statistical analysis was performed using two-way 
ANOVA with Tukey's post-hoc test. pIRF3 corrected integrated density/cell was 
expressed as fold change versus KB1P-G3 DMSO. Statistical analysis was performed 
using Kruskal-Wallis test with Dunn's post-hoc test. Error bars represent SEM of 3 
independent experiments (right panel). (D) At 72h post-treatment RNA was extracted and 
qPCR was performed. IFNβ, CCL5 and CXCL10 mRNA levels were normalized to 
GAPDH internal control. Error bars represent SEM of 3-4 independent experiments. 
Statistical analysis was performed using Kruskal-Wallis test with Dunn's post-hoc test.  
 
Figure 3. Olaparib induces pTBK1/pIRF3 signaling in tumor and dendritic cells from 
the K14-Cre-Brca1f/fTp53f/f GEMM of TNBC. 
(A-B) Tumors from 9 vehicle or olaparib-treated mice were harvested 5 days post-
treatment and subjected to flow cytometry for analysis of pTBK1 and pIRF3 expression. 
Scatter plots demonstrate increases in (A) pTBK1+ and pIRF3+ epithelial (EpCAM+) cells, 
(B) DCs (CD11b-CD11c+) and mature (CD11c+MHCII+) DCs in olaparib-treated animals. 
Error bars represent SD. Statistical analyses were performed using unpaired t-tests or 
unpaired t-tests with Welch’s correction. (C) Tumors from 9 vehicle or olaparib-treated 
mice were harvested at 5 days and analyzed for mRNA expression of IFNβ and CCL5 by 
qPCR. (D) KB1P-G3 and KB1P-G3+BRCA1 tumors from 5-6 vehicle or olaparib-treated 
mice were harvested at 5 days post-treatment and subjected to flow cytometry. Scatter 
plots demonstrate % pTBK1+ and pIRF3+ epithelial (EpCAM+) cells. Error bars represent 
SD. Statistical analyses were performed using two-way ANOVA with Tukey's post-hoc 
test.  
 
 
Figure 4. Olaparib activates the STING pathway more potently in HR-deficient TNBC 
cells compared to HR-proficient cells.  
The human TNBC isogenic cell line pair MDA-MB-436 control and BRCA1-reconstituted 
(+BRCA1) and a PARPi-resistant MDA-MB-436 clone, were treated with DMSO (0 μM 
olaparib) or the indicated doses of olaparib for 72h and subjected to (A) 
immunofluorescence staining with picogreen dye and anti-cGAS antibody. Error bars 
represent SEM of 3 independent experiments. Statistical analysis was performed using 
one-way ANOVA with Sidak's post-hoc test. Representative images of picogreen (green) 
and cGAS (red) stained micronuclei are shown (60x magnification). Scale bar, 8 μm. (B) 
ELISA for cGAMP production. cGAMP levels were expressed as fold change versus 
DMSO. Error bars represent SEM of 2 independent experiments. Statistical analysis was 
performed using Kruskal-Wallis test with Dunn's post-hoc test. (C) flow cytometric 
analysis of pTBK1Ser172 expression. Cisplatin (Cis; 1 μM) was used as positive control. 
Error bars represent SEM of 2-4 independent experiments. Statistical analysis was 
performed using one-way ANOVA with Sidak's post-hoc test (left panel) or two-way 
ANOVA with Tukey's post-hoc (right panel). (D) immunoblotting for pTBK1Ser172 and total 
TBK1 expression. Vertical black lines indicate points of blot cropping. (E) MDA-MB-436, 
HCC1937 and MDA-MB-231 human TNBC cell lines were treated according to their 7-
day IC50 values of olaparib and subjected to immunoblotting for pTBK1Ser172 and total 
TBK1 expression (F) and (G) Parental, control, BRCA1-reconstituted and PARPi-
resistant MDA-MB-436 cells were subjected to flow cytometric analysis of pIRF3Ser396 and 
pH2AXSer139 expression. Cisplatin (Cis; 1 μM) was used as positive control. Error bars 
represent SEM of 2-4 independent experiments. Statistical analysis was performed using 
one-way ANOVA with Sidak's post-hoc test or two-way ANOVA with Tukey's post-hoc. 
(E) qPCR analysis of IFNβ, CCL5 and CXCL10 mRNA levels in parental, control, BRCA1-
reconstituted and PARPi-resistant MDA-MB-436 cells, normalized to GAPDH internal 
control. Error bars represent SEM of 4 independent experiments. Statistical analyses 
were performed using Kruskal-Wallis test Dunn’s post-hoc test.  
 
Figure 5. STING or cGAS depletion abolishes olaparib-induced proinflammatory 
signaling. 
(A-B) Murine K14 CRISPR/Cas9 control or STING knockout (STING KO) cells were 
treated with DMSO (0 μM) or the indicated doses of olaparib, veliparib and talazoparib for 
72h and subjected to immunoblotting or qPCR. STING depletion, as shown by 
immunoblotting for total STING levels, abolishes PARPi-induced TBK1 phosphorylation 
and upregulation of IFNβ, CCL5 and CXCL10 mRNA levels, as measured by 
immunoblotting and qPCR, respectively. Arrows on the blots indicate specific bands and 
markers indicate MW (kDa). Error bars represent SEM of 3 independent experiments. 
Statistical analyses were performed using Kruskal-Wallis test with Dunn's post-hoc test. 
(C-D) K14 CRISPR/Cas9 control, STING KO with empty vector (KO+EV) or STING KO 
with STING-repletion (KO+STING) cells were treated with DMSO or olaparib for 72h and 
subjected to immunoblotting or qPCR. DMXAA (DMX; 10 μM) was used as positive 
control. STING repletion in KO cells, as shown by immunoblotting for total STING levels, 
rescues olaparib-induced TBK1 phosphorylation and induction of IFNβ, CCL5 and 
CXCL10 mRNA expression. Error bars represent SEM of 3 independent experiments. 
Statistical analyses were performed using Kruskal-Wallis test with Dunn's post-hoc test. 
(E-F) K14 CRISPR/Cas9 control or cGAS KO cells were treated with the indicated doses 
of olaparib or veliparib for 72h and subjected to immunoblotting or qPCR. cGAS depletion, 
as shown by immunoblotting for cGAS levels, abolishes PARPi-induced TBK1 
phosphorylation and upregulation of IFNβ, CCL5 and CXCL10 mRNA levels, as 
measured by immunoblotting and qPCR, respectively. Error bars represent SEM of 3 
independent experiments. Statistical analyses were performed using Kruskal-Wallis test 
with Dunn's post-hoc test. 
 
Figure 6. Intratumor STING depletion abolishes olaparib-induced T cell recruitment. 
(A) Immunoblotting for total STING protein levels in K14 control or STING KO tumors. (B-
C) Control and STING KO tumors from 4 mice treated with vehicle or olaparib for 5 days 
were subjected to flow cytometry. Scatter plots demonstrate increases in T cells (CD3+, 
CD8+ and granzyme B+) and pIRF3+ tumor (EpCAM+) and dendritic (CD11C+CD11B-) 
cells in olaparib-treated control but not STING KO tumors. Error bars represent SD. 
Statistical analyses were performed using one-way ANOVA with Sidak’s post-hoc test. 
(D) K14 CRISPR/Cas9 control or STING KO tumors were transplanted in syngeneic 
FVB/129P2 mice (5/group), which were treated with vehicle or olaparib. Tumor volumes 
(mm3) were measured at day 8 and 16. Error bars represent SD. Statistical analysis was 
performed using one-way ANOVA with Sidak’s post-hoc test. 
 
 






Supplementary Table S1: Antibodies 
FC, flow cytometry; WB, western blotting; IHC, immunohistochemistry; CST, Cell Signaling 
Technology; BD Biosc., BD Biosciences 
 
Antigen Conjugate Catalog # Manufacturer Method Dilution 
CD45 AlexaFluor488 103122 BioLegend FC 1:500 
CD3 AlexaFluor594 100240 BioLegend FC 1:1000 
CD8a PE/Cy7 100721 BioLegend FC 1:1000 
CD49b Pacific Blue 108917 BioLegend FC 1:500 
CD4 PE 100408 BioLegend FC 1:1000 
Granzyme B AlexaFluor647 515405 BioLegend FC 1:250 
mouse IgG1, κ AlexaFluor647 400135 BioLegend FC 1:500 
FoxP3 PerCP/Cy5.5 563902 BD Biosc. FC 1:100 
rat IgG2α, κ PerCP/Cy5.5 400531 BioLegend FC 1:100 
pTBK1 (Ser172) PE 13498 CST  FC 1:200 
rabbit IgG PE 5742S CST  FC 1:50 
pIRF3 (Ser396) AlexaFluor647 10327S CST FC 1:100 
rabbit IgG AlexaFluor647 2985S CST FC 1:800 
CD11b BV711 101241 BioLegend FC 1:1000 
CD11c BV650 564079 BD Biosc. FC 1:500 
MHC II (I-A/I-E) BV421 107631 BioLegend FC 1:1000 
Ep-CAM (CD326) BV605 118227 BioLegend FC 1:500 
p-histone H2A.X 
(Ser139) AlexaFluor647 613408 BioLegend FC 1:100 
pIRF3 (Ser396) - 29047 CST 
Indirect 
FC, IF 
 1:200, 
1:100 
Normal rabbit IgG  2729 CST Indirect 
FC 
1:500 
cGAS - SC-515777 Santa Cruz Biotechnology IF 1:100 
p-histone H2A.X 
(Ser139) - JBW301 EMD Millipore IF 1:500 
rabbit IgG  
(H+L) AlexaFluor568 A11011 Invitrogen 
Indirect 
FC, IF 
1:200, 
1:2000 
mouse IgG (H+L) AlexaFluor488 A11001 Invitrogen IF 1:2000 
TBK1/NAK - 3504S CST WB 1:1000 
cGAS  31659S CST WB 1:1000 
STING - NBP224683 IMGENEX WB 1:1000 
BRCA1 - GTX70111 GeneTex, Inc WB 1:1000 
β-Actin - A00702-200 GenScript WB 1:10000 
Vinculin - 4650S CST WB 1:1000 
rabbit IgG HRP NA934 GE Healthcare WB 1:2000 
mouse IgG HRP NA931 GE Healthcare WB 1:2000 
Supplementary Figure Legends 
Supplementary Figure S1  
(A) Tumor volume measurements from immunocompetent (FVB/129P) and 
immunodeficient (SCID) mice treated with vehicle or olaparib along with an isotype (iso) 
control or an anti-CD8 antibody. (B) Isotype- or anti-CD8-treated tumors were harvested 
at 5 days and subjected to flow cytometry. Scatter plot demonstrates significant reduction 
in CD8+ T cell numbers in mice treated with the CD8-depleting antibody. Also shown is a 
representative dotplot of CD4 vs CD8 cells in control and anti-CD8 antibody-treated mice. 
(C) Vehicle or olaparib-treated tumors were harvested at 0, 8 and 72h (left panel) or 10 
days (right panel) after treatment and subjected to immunohistochemical analysis for CD8 
expression. Statistical analyses were performed using one-way ANOVA with Tukey’s 
post-hoc test (left panel) or unpaired t-test (right panel). (D) Tumors from 9 vehicle or 
olaparib-treated mice were harvested 5 days and subjected to flow cytometry. Scatter 
plots show CD4+ cells, CD4+ T regulatory (Tregs) cells and the ratio of CD8 to Tregs. 
Histogram shows the proportion of different cell types as % of total live events. Error bars 
represent SD. Statistical analyses were performed using unpaired t-tests (with Welch’s 
correction if variances were significantly different) (**p=0.0018). (D) Additional 
independent repetitions (experiment 1 and 2) of flow cytometric T cell analysis in vehicle 
and olaparib-treated tumors. CD49b+ (natural killer; NK) cells and granzyme-B+ NK cells 
are also shown.  
Supplementary Figure S2 
Gating strategy used in flow cytometric analysis of T cells from harvested tumors. Debris 
was excluded on SSC vs FSC plot, and zombie aqua-positive i.e. non-viable cells were 
gated out. Live cells were analyzed for expression of CD45, CD3, CD8 and CD4 markers. 
CD3 expression was also analyzed out of CD45+ cells. A CD4 vs CD8 plot was used to 
distinguish CD8+CD4- and CD4+CD8- T cells out of CD45+ cells. FoxP3 (Tregs) and 
granzyme-B expression was analyzed out of CD4+CD8- and CD8+CD4- T cells, 
respectively. Representative black-colored density plots are shown for (A) vehicle-treated 
or (B) olaparib-treated stained samples. Blue-colored density plots are from isotype 
controls.  
Supplementary Figure S3  
(A) The murine K14-Cre BRCA1f/fp53f/f cell line (K14) was treated with DMSO (0 μM) or 
the indicated doses of olaparib for 72h and subjected to ELISA for cGAMP production. 
Error bars represent SEM of 3 independent experiments. (B) K14 cells were treated with 
the indicated doses of Olaparib for 72h and subjected to flow cytometric analysis of 
pTBK1Ser172, pIRF3Ser396 and pH2AXSer139 expression. DMXAA (10 μM, 24h) was used as 
a positive control. Error bars represent SEM of 2-4 independent experiments. Statistical 
analyses were performed using one-way ANOVA with Sidak’s post-hoc test. (C) Gating 
strategy used in flow cytometric analysis of pIRF3, pTBK1 and pH2AX in cell lines. Debris 
was excluded and zombie-aqua positive i.e. non-viable cells were gated out. Live cells 
were analyzed for pIRF3, pTBK1 and pH2AX expression. The examples shown are from 
unstained control, isotype controls, vehicle- and DMXAA-treated K14 cells. (D) K14 cells 
were treated with 0 or 5 μM olaparib for 24h and subjected to immunofluorescence 
staining for pH2AX and pIRF3. The number of cells displaying >5 γH2AX foci was 
quantified, and statistical analysis was performed using unpaired t-test. pIRF3 and pH2AX 
corrected integrated density/cell was expressed as fold change versus DMSO. Statistical 
analyses were performed using one-sample t-test. Error bars represent SEM of 3 
independent experiments. Representative images of DAPI (blue), γ-H2AX (green) and 
pIRF3 (red) stained cells are shown (20x magnification). Scale bar, 8 μm. (E) K14 cells 
were treated with the indicated doses of olaparib for 72h and analyzed for mRNA 
expression of IFNβ, CCL5 and CXCL10 (normalized to GAPDH internal control). 
Statistical analysis was performed using Kruskal-Wallis test Dunn’s post-hoc test. 
Supplementary Figure S4 
Gating strategy used in flow cytometric analysis of pTBK1 and pIRF3 from harvested 
tumors. Debris was excluded on SSC vs FSC plot and zombie aqua-positive i.e. non-
viable cells were gated out. Live cells were analyzed for expression of CD45, CD3, 
EpCAM, CD11B, CD11C, MHCII, pTBK1 and pIRF3. pTBK1- or pIRF3-positive tumor 
cells were defined from EpCAM (epithelial) and pTBK1 or pIRF3 double positive live cells. 
For DC identification, CD45+ live cells were gated on a CD3 vs SSC plot and CD3- i.e. 
non-T cells were analyzed for expression of CD11B, CD11C and MHCII markers. CD11B-
CD11C+ (pure) and CD11C+MHCII+ (mature) DCs were then analyzed for expression of 
pTBK1 and pIRF3. Representative black-colored density plots are shown for (A) vehicle-
treated or (B) olaparib-treated stained samples. Blue-colored density plots are from 
isotype and unstained controls, as indicated on the plot. 
Supplementary Figure S5 
Bone marrow derived DCs (CD11C+CD11B-) from 2-4 mice were treated with DMSO 
(vehicle), olaparib (5 μM) or DMXAA (10 μM) for 20h and subjected to flow cytometry. (A) 
Scatter plots demonstrate increases in pTBK1high, CD40+ and MHCII+ DCs by DMXAA 
but not olaparib. Median fluorescence intensity (MFI) for pTBK1 is also shown. Statistical 
analyses were performed using one-way ANOVA with Tukey’s post-hoc test. Error bars 
represent SD. (B) Gating strategy. Debris was excluded on SSC vs FSC plot and zombie 
aqua-positive i.e. non-viable cells were gated out. For DC identification, CD45+ live cells 
were gated on CD11B vs CD11C plot and pure DCs (CD11C+CD11B-) were analyzed 
for expression of MHCII (maturation), CD40 (activation) and pTBK1 markers. 
Representative black-colored density plots are shown for DMSO-treated (upper panel) or 
DMXAA-treated (left panel) stained samples. Histogram was used for pTBK1 MFI 
measurement. Blue-colored density plots are from isotype and unstained controls, as 
indicated on the plot.  
Supplementary Figure S6 
(A) Immunoblotting for BRCA1 expression in control and BRCA1-reconstituted MDA-MB-
436 cells. (B) Cell viability assays in human TNBC cell lines treated with increasing doses 
of olaparib for 7 days. IC50 values were derived using non-linear regression. Error bars 
represent SEM of 2-4 independent experiments. Statistical analyses were performed 
using one-way ANOVA with Sidak’s post-hoc test Representative survival curves are 
shown on the right. Error bars on the curves represent SD from 3 technical replicates.  
(C) Human TNBC cell lines were treated with the same doses of olaparib for 72h and 
subjected to immunoblotting pTBK1Ser172, total TBK1 and STING. (D) Immunoblotting for 
STING expression in parental and PARPi-resistant MDA-MB-436 cells. (E) MDA-MB-436 
control and BRCA1-reconstituted cells were treated with 0 or 1 μM olaparib for 24h and 
subjected to immunofluorescence staining for pH2AX and pIRF3. The number of cells 
displaying >5 γH2AX foci was quantified, and statistical analysis was performed using 
two-way ANOVA with Tukey's post-hoc test. pIRF3 corrected integrated density/cell was 
expressed as fold change versus DMSO. Statistical analysis was performed using 
Kruskal-Wallis test with Dunn's post-hoc test. Error bars represent SEM of 3 independent 
experiments. Representative images of DAPI (blue), γ-H2AX (green) and pIRF3 (red) 
stained cells are shown below (20x magnification). Scale bar, 8 μm. (F) HCC1937 cells 
were treated with 0 or 10 μM olaparib for 72h and subjected to flow cytometric analysis 
of pIRF3 expression and qPCR analysis of IFNβ, CCL5 and CXCL10 mRNA level 
(normalized to GAPDH internal control). Error bars represent SEM of 3-4 independent 
experiments. Statistical analysis was performed using unpaired t-test (left panel) or one-
sample t-test (right panel).  
Supplementary Figure S7 
(A) Veliparib and talazoparib IC50 values from 7-day cell viability assays in control and 
BRCA1-reconstituted MDA-MB-436 cells. Error bars represent SEM of 2 independent 
experiments. (B) Lysates from DMSO (-), veliparib (2 μM) or talazoparib (5 nM) treated 
(72h) MDA-MB-436 control and BRCA1-reconstituted cells were analyzed by ELISA for 
cGAMP levels, which were expressed as fold change versus DMSO. Statistical analysis 
was performed using Kruskal-Wallis test with Dunn's post-hoc test. Error bars represent 
SEM of 2 independent experiments. (C-D) MDA-MB-436 control and BRCA1-
reconstituted cells were treated with the indicated doses of veliparib (V) in μM or 
talazoparib (T) in nM and subjected to immunoblotting for pTBK1Ser172, total TBK1 and 
STING, or qPCR for analysis of IFNβ, CCL5 and CXCL10 mRNA levels. Error bars 
represent SEM of 4 independent experiments. Statistical analyses were performed using 
Kruskal-Wallis test with Dunn's post-hoc test. (E) Murine K14 CRISPR/Cas9 control or 
STING KO cells were treated with increasing doses of PARP inhibitors for 7 days and 
subjected to cell viability assays to derive IC50 values. Error bars represent SEM of 3-4 
independent experiments. Statistical analysis was performed using unpaired t-test. 
(ns=not significant). Representative survival curves are shown on the right. Error bars on 
the curves represent SD from 3 technical replicates.  
 







